Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Glial attenuation with ibudilast in the treatment of medication overuse headache: a double-blind, randomized, placebo-controlled pilot trial of efficacy and safety
Author: Johnson, J.L.
Kwok, Y.H.
Sumracki, N.M.
Swift, J.E.
Hutchinson, M.R.
Johnson, K.
Williams, D.B.
Tuke, J.
Rolan, P.E.
Citation: Headache, 2015; 55(9):1192-1208
Publisher: Wiley
Issue Date: 2015
ISSN: 0017-8748
Statement of
Jacinta L. Johnson, Yuen H. Kwok , Nicole M. Sumracki , James E. Swift, Mark R. Hutchinson , Kirk Johnson , Desmond B. Williams , Jonathon Tuke , and Paul E. Rolan
Abstract: Background Medication overuse headache (MOH) is a condition bordering between a chronic pain condition and a substance dependence disorder. Activation of immunocompetent glial cells in the central nervous system has been linked to both pathological pain and drug addiction/reward. Preclinically, ibudilast attenuates glial activation and is able to reduce neuropathic pain and markers of substance dependence. We therefore hypothesized ibudilast would reduce headache burden and opioid analgesic requirements in patients with opioid overuse headache. Objective To determine if treatment with ibudilast provides a greater reduction in headache index than placebo in MOH patients consuming opioids. Methods Participants with MOH who were using opioids were randomized via computer-generated code to ibudilast 40 mg or placebo twice daily for 8 weeks in a double-blind, parallel groups study. Before randomization participants completed a 4-week baseline headache diary. During treatment, headache diary data collection continued and participants attended 4 study visits during which quantitative sensory testing was performed. Blood samples for immune biomarker analyses were collected before and after treatment in a subgroup of participants. Results Thirty-four participants were randomized, 13 of 15 randomized to ibudilast and 17 of 19 randomized to placebo completed treatment. Ibudilast was generally well-tolerated with mild, transient nausea reported as the most common adverse event (66.7% vs 10.5% in placebo group). Results are shown as mean (SD). At the end of treatment no differences in the primary outcome average daily headache index (placebo 62 [44] vs ibudilast 77 [72] groups, difference −15, CI −65 to 35 h × numerical rating scale), or secondary outcomes headache frequency (placebo 23 [8.1] vs ibudilast 24.5 [6.2], difference −1.5, CI −7.7 to 4.8 days/month) and opioid intake (placebo 20.6 [43] vs ibudilast 19 [24.3], difference 1.6, CI −31.5 to 34.8 mg morphine equivalent) were observed between placebo and ibudilast groups. Conclusions Using the current dosing regimen, ibudilast does not improve headache or reduce opioid use in patients with MOH without mandated opioid withdrawal. However, it would be of interest to determine in future trials if ibudilast is able to improve ease of withdrawal during a forced opioid down-titration when incorporated into an MOH detoxification program.
Keywords: Neuroglia
Vasodilator Agents
Area Under Curve
Pilot Projects
Double-Blind Method
ROC Curve
Middle Aged
Headache Disorders, Secondary
Rights: © 2015 American Headache Society
DOI: 10.1111/head.12655
Grant ID:
Published version:
Appears in Collections:Aurora harvest 7
Mathematical Sciences publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.